Patients with HER2-negative advanced-stage gastric or gastro-oesophageal junction (G/GEJ) adenocarcinomas typically receive chemotherapy with or without an anti-PD-1 antibody as first-line treatment. Now, data from the phase III COMPASSION-15 trial show that combination of the PD-1 Ă— CTLA4 bispecific antibody cadonilimab plus chemotherapy is also efficacious in this setting.
In this trial, conduced in China, 610 patients were randomly allocated (1:1) to receive chemotherapy (oxaliplatin–capecitabine) plus either cadonilimab or placebo. Overall survival (OS) was the primary end point.
This is a preview of subscription content, access via your institution
Access options
/* style specs start */ /* style specs end */
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on SpringerLink Instant access to full article PDF Buy now
Prices may be subject to local taxes which are calculated during checkout
/* style specs start */ style { display: none !important; } .LiveAreaSection * { align-content: stretch; align-items: stretch; align-self: auto; animation-delay: 0s; animation-direction: normal; animation-duration: 0s;